A phase I/IItrial of MYO‐029 in adult subjects with muscular dystrophy

Abstract

This trial supports the hypothesis that systemic administration of myostatin inhibitors provides an adequate safety margin for clinical studies. Further evaluation of more potent myostatin inhibitors for stimulating muscle growth in muscular dystrophy should be considered.